vTv Therapeutics Inc.
VTVT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.44 | -0.13 | -0.32 |
| FCF Yield | -31.75% | -79.58% | -29.99% | -30.97% |
| EV / EBITDA | -1.92 | -0.58 | -1.60 | -2.85 |
| Quality | ||||
| ROIC | -72.75% | -3,359.95% | -87.00% | -124.38% |
| Gross Margin | 100.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.11 | 0.94 | 0.80 | 1.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -20.42% | -100.00% | -31.99% | 13.16% |
| Free Cash Flow Growth | -32.63% | -24.98% | 20.93% | -7.27% |
| Safety | ||||
| Net Debt / EBITDA | 1.62 | 0.34 | 0.46 | 0.71 |
| Interest Coverage | 0.00 | -1,961.69 | -1,502.67 | -1,805.17 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 22.25 | 0.00 | 2,245.71 | 5.19 |